The small medtech company is celebrating great success on the market for bone replacement products and on the stock exchange. Simon Götschmann, fund manager of Arkudos 130/30 Swiss Equity Alpha and Kuros Investor, shares his views on the stock with Finanz+Wirtschaft.
Comments